China dominates big licensing deals as M&A starts 2026 with a bangnews2026-04-15T13:00:51+00:00April 15th, 2026|Endpoints News|
China biotech’s CRISPR therapy suggests US drugmakers will face competitionnews2026-04-10T15:54:15+00:00April 10th, 2026|Endpoints News|
China-based CAR-T company Oricell raises $40M more as it looks to go publicnews2026-04-10T10:28:17+00:00April 10th, 2026|Endpoints News|
China-based AI biotech Ailux hires CSO, eyes clinic in 2027news2026-04-09T14:00:15+00:00April 9th, 2026|Endpoints News|
Proposed FDA budget sets Makary up to boost US biotechnews2026-04-06T18:38:19+00:00April 6th, 2026|Endpoints News|
China’s Syneron raises $150M for peptides, adding to last year’s $100Mnews2026-04-06T10:50:19+00:00April 6th, 2026|Endpoints News|
To counter China, FDA chief wants to speed new drug trial processnews2026-04-01T19:15:42+00:00April 1st, 2026|Endpoints News|
Eli Lilly to pay $115M upfront to Insilico in AI drug discovery dealnews2026-03-30T14:07:39+00:00March 30th, 2026|Endpoints News|
#ACC26: Braveheart Bio’s Hengrui-originated pill posts China data in heart muscle diseasenews2026-03-30T13:30:46+00:00March 30th, 2026|Endpoints News|
AstraZeneca’s in vivo CAR-T led to early responses, but one death in China trialnews2026-03-27T12:00:35+00:00March 27th, 2026|Endpoints News|
